Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response

Atherosclerosis

Volumn 139, Issue 2, 1998, Pages 307-315

  Feingold, Kenneth R ^a   Memon, Riaz A ^a   Moser, Arthur H ^a   Grunfeld, Carl ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Endotoxin; IL 1; TNF

Indexed keywords

ARYLESTERASE; ENDOTOXIN; INTERLEUKIN 1; MESSENGER RNA; TUMOR NECROSIS FACTOR;

ACUTE PHASE RESPONSE; ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; ENZYME ACTIVITY; HAMSTER; LIPID METABOLISM; LIPOPROTEIN METABOLISM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

ACUTE-PHASE REACTION; ANIMALS; ARYLDIALKYLPHOSPHATASE; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTERASES; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; LIVER; MALE; MESOCRICETUS; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031831615     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00084-7     Document Type: Article

References (51)

1. Hardardottir I., Grunfeld C., Feingold K.R. Effects of endotoxin and cytokines on lipid metabolism. Curr Opin Lipidol. 5:1994;207-215.
2. Acute Phase Proteins. In: Mackiewicz A, Kushner I, Bauman H, editors. Molecular Biology, Biochemistry and Clinical Applications. Boca Raton, FL: CRC Press, 1993.
3. Feingold K.R., Staprans I., Memon R., Moser A.H., Shigenaga J.K., Doerrler W., Dinarello C.A., Grunfeld C. Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance. J Lipid Res. 33:1992;1765-1776.
4. Gouni I., Oka K., Etienne J., Chan L. Endotoxin induced hypertriglyceridemia is mediated by suppression of lipoprotein lipase at a post-transcriptional level. J Lipid Res. 34:1993;139-146.
5. Feingold K.R., Hardardottir I., Memon R., Krul E.J.T., Moser A.H., Taylor J.M., Grunfeld C. The effect of endotoxin on cholesterol biosynthesis and distribution in serum lipoproteins in Syrian hamsters. J Lipid Res. 34:1993;2147-2158.
6. Feingold K.R., Pollock A.S., Moser A.H., Shigenaga J.K., Grunfeld C. Discordant regulation of proteins of cholesterol metabolism during the acute phase response. J Lipid Res. 36:1995;1474-1482.
7. Feingold K.R., Spady D.K., Pollock A.S., Moser A.H., Grunfeld C. Endotoxin, TNF and IL-1 decrease cholesterol 7-alpha-hydroxylase mRNA levels and activity. J Lipid Res. 37:1996;223-228.
8. Ettinger W.H., Miller L.D., Albers J.J., Smith T.K., Parks J.S. Lipopolysaccharide and tumor necrosis factor cause a fall in plasma concentration of lecithin: cholesterol acyltransferase in cynomologus monkeys. J Lipid Res. 31:1990;1099-1107.
9. Hoffman J.S., Benditt E.P. Changes in high density lipoprotein content following endotoxin administration in the mouse. Formation of serum amyloid protein-rich subfractions. J Biol Chem. 257:1982;90510-90517.
10. Hardardottir I., Kunitake S.T., Moser A.H., Doerrler W., Rapp J.H., Grunfeld C., Feingold K.R. Endotoxin and cytokines increase hepatic mRNA levels and serum concentrations of apolipoprotein J (Clusterin) in Syrian hamsters. J Clin Invest. 94:1994;1304-1309.
11. Auerbach B.J., Parks J.S. Lipoprotein abnormalities associated with lipopolysaccharide induced lecithin cholesterol acyltransferase and lipase deficiency. J Biol Chem. 264:1989;10264-10270.
12. Ly H., Francone O.L., Fielding C.J., Shigenaga J.K., Moser A.H., Grunfeld C., Feingold K.R. Endotoxin and TNF lead to reduced plasma LCAT activity and decreased hepatic LCAT mRNA levels in Syrian hamsters. J Lipid Res. 36:1995;1254-1263.
13. Majucci-Magoulas L., Moulin P., Jiang X.C., Richardson H., Walsh A., Breslow J.L., Tall A. Decreased cholesterol ester transfer protein (CETP) mRNA and protein and increased high density lipoprotein after lipopolysaccharide administration in human CETP transgenic mice. J Clin Invest. 95:1995;1587-1594.
14. Hardardottir I., Moser A.H., Fuller J., Fielding C., Feingold K.R., Grunfeld C. Endotoxin and cytokines decrease serum levels and extra hepatic protein and mRNA levels of cholesterol ester transfer protein in Syrian hamsters. J Clin Invest. 97:1996;2585-2592.
15. Jiang X.C., Bruce C. Regulation of murine plasma phospholipid transfer protein activity and mRNA levels by lipopolysaccharide and high cholesterol diet. J Biol Chem. 270:1995;17133-17138.
16. Sammelkorpi K., Valtonen V., Kerttula Y., Nikkila E., Taskinen M.R. Change in serum lipoprotein pattern induced by acute infections. Metabolism. 37:1988;859-865.
17. Fielding C.J., Fielding P.E. Molecular physiology of reverse cholesterol transport. J Lipid Res. 36:1995;211-228.
18. Hoffman J.S., Benditt E.P. Plasma clearance kinetics of the amyloid related high density lipoprotein, serum amyloid protein (apo SAA) in the mouse. Evidence for rapid apo SAA clearance. J Clin Invest. 71:1983;926-934.
19. Kisilensky R., Subrahamanyan L. Serum amyloid A changes high density lipoproteins cellular affinity. A clue to serum amyloid A's principal function. Lab Invest. 66:1992;778-785.
20. Hessler J.R., Robertson A.L., Chisolm G.M. Jr. LDL induced cytotoxocity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis. 32:1979;213-229.
21. Parthesarathy S., Barnett J., Fong L.G. High density lipoproteins inhibit the oxidative modification of low density lipoprotein. Biochim Biophys Acta. 1044:1990;275-283.
22. Navab M., Berliner J.A., Watson A.D., Hama S.Y., Territo M.C., Lusis A.J., Shih D.M., Van Lenten B.J., Frank J.S., Demer L.L. The yin and yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lymon Duff Memorial Lecture. Arteriosclerosis. 16:1996;831-842.
23. Van Lenten B.J., Hama S.Y., de Beer F.C., Staffori D.M., McIntyre T.M., Prescott S.M., La Du B.N., Fogelman A.M., Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. J Clin Invest. 96:1995;2758-2767.
24. Mackness M.I., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low density lipoprotein. FEBS. 286:1991;152-154.
25. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., Navab M. Protective effect of high density lipoprotein associated paraoxonase. J Clin Invest. 96:1995;2882-2891.
26. Hardardottir I., Moser A.H., Memon R.A., Grunfeld C., Feingold K.R. Effects of TNF, IL-1 and the combination of both cytokines on cholesterol metabolism in Syrian hamsters. Lymphok Cytok Res. 13:1994;161-166.
27. Furlong C.E., Richter R.J., Seidel S.L., Costa L.G., Motulsky A.G. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrites and parathion by plasma paraoxonase/arylesterase. Anal Biochem. 180:1989;242-247.
28. Morrow J.F., Stearman R.J., Peltzman C.G., Potter D.A. Induction of hepatic synthesis of serum amyloid A protein and actin. Proc Natl Acad Sci USA. 78:1981;4718-4722.
29. Hassett C., Richter R.J., Humbert R., Chapline C., Crabb J.W., Omiecinski C.J., Furlong C.E. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: The mature protein retains its signal sequence. Biochemistry. 30:1991;10141-10149.
30. Blatter M.C., James R.W., Messmer S., Barja F., Pometta D. Identification of a distinct human high density lipoprotein subspecies defined by a lipoprotein associated protein, K-45: identity of K-45 with paraoxonase. Eur J Biochem. 211:1993;871-879.
31. Mackness M.I., Hallam S.D., Peard T., Warner S., Walker C.H. The separation of sheep and human serum 'A'-esterase activity into lipoprotein fraction by ultra centrifugation. Comp Biochem Physiol B Comp Biochem. 82:1985;675-677.
32. Kelso G.J., Stuart W.D., Richter R.J.et al. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 33:1994;332-839.
33. Mattila K.J. Dental infections as a risk factor for acute myocardial infarction. Eur Heart J. 14(Suppl K):1993;51-53.
34. Mattila K.J., Valtonen V.V., Nieminen M., Huttunen J.K. Dental infection and the risk of new coronary events: prospective study of patients with documented coronary artery disease. Clin Infect Dis. 20:1995;588-592.
35. Saikku P., Leinonen M., Tenkanen L., Linnanmaki E., Ekman M.R., Manninen V., Manterri M., Frick M.H., Huttunen J.K. Chronic chlamydia penumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 116:1992;273-378.
36. Thom D.H., Grayston J.T., Siscovick D.S., Wang S.P., Weiss N.S., Daling J.R. Association of prior infection with chlamydia pneumoniae and angiographically demonstrated coronary artery disease. J Am Med Assoc. 268:1992;68-72.
37. Melnick S.L., Shahar E., Folsom A.R., Grayston J.T., Sorlie P.O., Wang S.P., Szkle M. Past infection by chlamydia pneumoniae strain TWAR and asymptomatic carotid atheroslcerosis. Atherosclerosis Risk in Communities (ARIC) Study Investigation. Am J Med. 95:1993;499-504.
38. Mendall M.A., Carrington D., Strachan D., Patel P., Molineaux W., Levi J., Toosey T., Camm A.J., Northfield T.C. Chlamydia pneumoniae: risk factors for sero positivity and association with coronary heart disease. J Infect. 30:1995;121-128.
39. Mendall M.A., Goggin P.M., Molineaux N., Levy J., Toosey T., Strachen D., Camm A.J., Northfield T.C. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J. 71:1994;437-439.
40. Patel P., Mendall M.A., Carrington D., Strachan D.P., Leatham E., Molineaux N., Levy J., Blakeston C., Seymour C.A., Camm A.J.et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. Br Med J. 311:1995;711-714.
41. Niemela S., Karttunen T., Korhonen T.et al. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations? Heart. 75:1996;573-575.
42. Jousilahti P., Vartiainen E., Tuomilehto J., Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet. 348:1996;567-572.
43. Kuller L.H., Tracy R.P., Shaten J., Meilahn E.N. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case control study. Am J Epidemiol. 144:1996;537-547.
44. Mendall M.A., Patel P., Ballam L., Strachan D., Northfield T.C. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. Br Med J. 312:1996;1061-1065.
45. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 336:1997;973-979.
46. Monson R.R., Hall A.P. Mortality among arthritics. J Chron Dis. 29:1976;459-467.
47. Koota K., Isomaki H., Motru O. Death rate and census of death in RA patients during a period of five years. Scand J Rheumatol. 6:1997;241-244.
48. Allebeck P. Increased mortality in rheumatoid arthritis. Scand J Rheumatol. 11:1982;81-86.
49. Prior P., Symmons D.P., Scott D.L., Brown R., Hawkins C.F. Cause of death in rheumatoid arthritis. Br J Rheumat. 23:1984;92-99.
50. Shih D.M., Gu L., Hama S., Xia Y.-R., Navab M., Fogelman A.M., Lusis A.J. Genetic dietary regulation of serum paraoxonase expression and its role in atherogneesis in a mouse model. J Clin Invest. 97:1996;1630-1639.
51. Castellani L.W., Naveb M., Van Lenten B.J., Hedrick C.C., Hama S.Y., Goto A.M., Fogelman A.M., Lusis A.J. Over-expression of apolipoprotein AII in transgenic mice converts high density lipoproteins to pro-inflammatory particles. J Clin Invest. 100:1997;464-474.